Details of Disease

General Information of Disease (ID: DISE4C4D)

Disease Name	Onychomycosis
Synonyms	cellulitis and abscess; tinea unguium; onychomycosis due to dermatophyte; onychomycosis; nail dermatophytosis; dermatophytosis of nail; dermatophytic onychomycosis; dermatophytic onychia; cellulitis and abscess of upper arm and forearm; cellulitis and abscess of trunk; cellulitis and abscess of gluteal region; cellulitis and abscess of finger and toe; cellulitis and abscess of finger; cellulitis and abscess of face; cellulitis and abscess of buttock
Disease Class	EE12: Nail/perionychium infection
Definition	A fungal infection of the nail, usually caused by dermatophytes; yeasts; or nondermatophyte molds.
Disease Hierarchy	DISM7JPJ: Dermatophytosis DISLB7V1: Nail infection DISE4C4D: Onychomycosis
ICD Code	ICD-11 ICD-11: EE12.1 Expand ICD-11 'EE12.1
Disease Identifiers	MONDO ID MONDO_0001628 MESH ID D014009 UMLS CUI C0040261 MedGen ID 11825 HPO ID HP:0012203 SNOMED CT ID 414941008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 11 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amorolfine	DMI0G4Y	Approved	Small molecular drug	[1]
Ciclopirox	DMN5T2A	Approved	Small molecular drug	[2]
Efinaconazole	DMFA9MV	Approved	Small molecular drug	[3]
Ferric maltol	DMVYD7I	Approved	NA	[4]
Griseofulvin	DMK54YG	Approved	Small molecular drug	[5]
Miconazole	DMPMYE8	Approved	Small molecular drug	[6]
Oteseconazole	DM7R145	Approved	Small molecular drug	[7]
Tavaborole	DM3ED1A	Approved	Small molecular drug	[1]
Terbinafine	DMI6HUW	Approved	Small molecular drug	[8]
Tioconazole	DMNYPGS	Approved	Small molecular drug	[9]
Triacetin	DM0AEPG	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MOB015B	DM7R2TU	Phase 3	NA	[8]
NAB-001	DM9OWZU	Phase 3	NA	[10]
HXP124	DMYH9ZB	Phase 2	Peptide	[11]
ME1111	DM2VPMH	Phase 2	NA	[12]
NB-002	DML8S50	Phase 2	NA	[13]
NP-213	DMPILEN	Phase 2	NA	[14]
NVXT	DMST2R6	Phase 2	NA	[8]
SB208	DMCTMOZ	Phase 2	NA	[8]
TMI-358	DMLD9LH	Phase 2	NA	[15]
VT-1129	DMCGK9H	Phase 2	NA	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BC-ONY-01	DM8DVVW	Investigative	NA	[16]
K-101	DMO2HBF	Investigative	Small molecular drug	[16]
Penecure	DMFMLTO	Investigative	NA	[16]
XEL-003FL	DM5A0NX	Investigative	NA	[16]
XEL-003FP	DMHZWP2	Investigative	NA	[16]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLEC7A	OTRTBH27	moderate	Genetic Variation	[17]
LYST	OTIUB1B3	Strong	Biomarker	[18]
POLR2A	OTHJQ1DZ	Strong	Biomarker	[19]
SLN	OTERIU75	Strong	Biomarker	[20]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Ciclopirox FDA Label
3	Efinaconazole FDA Label
4	ClinicalTrials.gov (NCT01352221) Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2). U.S. National Institutes of Health.
5	Griseofulvin FDA Label
6	Miconazole FDA Label
7	ClinicalTrials.gov (NCT02267356) A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail. U.S. National Institutes of Health.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075915.
10	ClinicalTrials.gov (NCT01208168) Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails. U.S. National Institutes of Health.
11	Clinical pipeline report, company report or official report of Hexima.
12	ClinicalTrials.gov (NCT02022215) Efficacy and Safety Study of ME1111 in Patients With Onychomycosis. U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT00453271) Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail. U.S. National Institutes of Health.
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030921)
15	ClinicalTrials.gov (NCT01093118) A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis. U.S. National Institutes of Health.
16	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
17	Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009 Oct 29;361(18):1760-7. doi: 10.1056/NEJMoa0901053.
18	Evaluation of Chitine synthase (CHS1) polymerase chain reaction assay in diagnosis of dermatophyte onychomycosis.J Mycol Med. 2012 Sep;22(3):249-55. doi: 10.1016/j.mycmed.2012.07.050. Epub 2012 Aug 16.
19	Clinical spectrum of exophiala infections and a novel Exophiala species, Exophiala hongkongensis.J Clin Microbiol. 2013 Jan;51(1):260-7. doi: 10.1128/JCM.02336-12. Epub 2012 Nov 14.
20	SLN- and NLC-encapsulating antifungal agents: skin drug delivery and their unexplored potential for treating onychomycosis.Curr Pharm Des. 2017 Nov 14. doi: 10.2174/1381612823666171115112745. Online ahead of print.